GlassScriptPhysician profile
Snehal A Damle
NPI 1174560015
$548.84
in general payments reported to CMS, 2019-2025
11 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.05 · 2020: $71.28 · 2021: $26.15 · 2022: $178 · 2023: $31.30 · 2024: $18.23 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150 · Food and Beverage: $71.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
| Food and Beverage | $71.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $150.00 | 2025 | Mektovi, Braftovi, Lorbrena |
| Intuitive Surgical, INC. | $91.33 | 2022 | |
| Seagen INC. | $90.31 | 2019-2022 | |
| Lilly USA, LLC | $71.28 | 2020 | |
| Pharmacosmos Therapeutics INC. | $31.30 | 2023 | Monoferric |
| Lexicon Pharmaceuticals, INC. | $27.47 | 2019 | |
| Pfizer INC. | $22.25 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.23 | 2024 | |
| Daiichi Sankyo INC. | $14.23 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Snehal Damle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.